Human VEGF-C Quantikine ELISA Kit

Catalog # Availability Size / Price Qty
DVEC00
Control Products Available
Human VEGF-C ELISA Cell Culture Supernate/Saliva Standard Curve
3 Images
Product Details
Procedure
Citations (39)
FAQs
Supplemental Products
Reviews (3)

Human VEGF-C Quantikine ELISA Kit Summary

Assay Type
Solid Phase Sandwich ELISA
Format
96-well strip plate
Assay Length
4.5 hours
Sample Type & Volume Required Per Well
Cell Culture Supernates (50 uL), Serum (10 uL), EDTA Plasma (50 uL), Platelet-poor Plasma (50 uL), Heparin Plasma (50 uL), Saliva (50 uL)
Sensitivity
48.4 pg/mL
Assay Range
109.0 - 7,000 pg/mL (Cell Culture Supernates, Serum, EDTA Plasma, Platelet-poor Plasma, Heparin Plasma, Saliva)
Specificity
Natural human VEGF-C, recombinant human VEGF-C (wild type), and recombinant human VEGF-C (Cys156Ser substituted)
Cross-reactivity
< 0.5% cross-reactivity observed with available related molecules.Cross-species reactivity not tested.
Interference
No significant interference observed with available related molecules.

Product Summary

The Quantikine Human VEGF-C Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human VEGF-C in cell culture supernates, serum, plasma, and saliva. It contains NS0-expressed recombinant human VEGF-C (Cys156Ser substituted) and has been shown to accurately quantitate the recombinant factor. Results obtained using recombinant human VEGF-C (wild type) and natural human VEGF-C showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human VEGF-C.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision

Cell Culture Supernates, Saliva

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean 572 1622 3243 520 1527 3069
Standard Deviation 39.3 54.4 136 50.1 102 200
CV% 6.9 3.4 4.2 9.6 6.7 6.5

Serum, EDTA Plasma, Platelet-poor Plasma, Heparin Plasma

Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 40 40 40
Mean 512 1543 3195 514 1540 3066
Standard Deviation 33.8 54.2 136 43.6 110 198
CV% 6.6 3.5 4.3 8.5 7.2 6.4

Recovery

The recovery of VEGF-C spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Supernates (n=4) 107 93-115
EDTA Plasma (n=4) 101 96-110
Heparin Plasma (n=4) 97 88-103
Serum (n=4) 99 89-106

Linearity

To assess the linearity of the assay, samples containing and/or spiked with high concentrations of VEGF-C were serially diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human VEGF-C ELISA Linearity

Data Examples

Human VEGF-C ELISA Cell Culture Supernate/Saliva Standard Curve

Human VEGF-C ELISA Serum/Plasma Standard Curve

Product Datasheets

Preparation and Storage

Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: VEGF-C

Vascular endothelial growth factor C (VEGF-C) is a homodimeric ligand of VEGF R3/Flt-4 and is synthesized with N- and C-terminal propeptides. Fully processed VEGF-C containing only the VEGF homology domain can additionally bind and activate VEGF R2/KDR/Flk-1. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis. Both the ligand and receptor are usually co-expressed at sites of lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, neoangiogenesis, and vessel sprouting, resulting in enhanced lymph flow and metastasis to regional lymph nodes.

Long Name:
Vascular Endothelial Growth Factor C
Entrez Gene IDs:
7424 (Human); 22341 (Mouse)
Alternate Names:
Flt4 ligand; Flt4-L; vascular endothelial growth factor C; Vascular endothelial growth factor-related protein; VEGFC; VEGF-C; VRPFLT4 ligand DHM
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Assay Procedure

Refer to the product for complete assay procedure.

Bring all reagents and samples to room temperature before use. It is recommended that all samples, standards, and controls be assayed in duplicate.
  1.   Prepare all reagents, standard dilutions, and samples as directed in the product insert.
  2.   Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.

  3. 100 µL Assay Diluent
  4.   Add 100 µL of Assay Diluent to each well.

  5. 50 µL Standard, Control, or Sample
  6.   Add 50 µL of Standard, control, or sample to each well. Cover with a plate sealer, and incubate at room temperature for 2 hours on a horizontal orbital microplate shaker.
  7.   Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.

  8. 200 µL Conjugate
  9.   Add 200 µL of Conjugate to each well. Cover with a new plate sealer, and incubate at room temperature for 2 hours on the shaker.
  10.   Aspirate and wash 4 times.

  11. 200 µL Substrate Solution
  12.   Add 200 µL Substrate Solution to each well. Incubate at room temperature for 30 minutes on the benchtop. PROTECT FROM LIGHT.

  13. 50 µL Stop Solution
  14.   Add 50 µL of Stop Solution to each well. Read at 450 nm within 30 minutes. Set wavelength correction to 540 nm or 570 nm.

Citations for Human VEGF-C Quantikine ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

39 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Comparison of lung ultrasound and other volumetric methods in peritoneal dialysis patients
    Authors: M Sevinc, NB Hasbal, T Basturk, PN Ozcafer, BB Kocas, K Kilickesme, A Ozel, T Sakaci, E Ahbap, A Unsal, Y Koc
    Medicine, 2021;100(3):e23856.
    Species: Human
    Sample Types: Serum
  2. Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis
    Authors: WN Li, KY Hsiao, CA Wang, N Chang, PL Hsu, CH Sun, SR Wu, MH Wu, SJ Tsai
    Proc Natl Acad Sci U S A, 2020;0(0):.
    Species: Human
    Sample Types: Serum
  3. Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003
    Authors: AZ Dudek, LC Liu, S Gupta, TF Logan, EA Singer, M Joshi, YN Zakharia, JM Lang, JK Schwarz, A Al-Janadi, AS Alva
    J. Clin. Oncol., 2020;38(11):1138-1145.
    Species: Human
    Sample Types: Serum
  4. GRK2-Dependent HuR Phosphorylation Regulates HIF1&alpha Activation under Hypoxia or Adrenergic Stress
    Authors: C Reglero, V Lafarga, V Rivas, Á Albitre, P Ramos, SR Berciano, O Tapia, ML Martínez-C, F Mayor, P Penela
    Cancers (Basel), 2020;12(5):.
    Species: Human
    Sample Types: Cell Lysates
  5. Antibody-mediated delivery of VEGF-C potently reduces chronic skin inflammation
    Authors: S Schwager, S Renner, T Hemmerle, S Karaman, ST Proulx, R Fetz, AM Golding-Oc, P Probst, C Halin, D Neri, M Detmar
    JCI Insight, 2018;3(23):.
    Species: Mouse
    Sample Types: Serum
  6. RIP1 regulates TNF-?-mediated lymphangiogenesis and lymphatic metastasis in gallbladder cancer by modulating the NF-?B-VEGF-C pathway
    Authors: CZ Li, XJ Jiang, B Lin, HJ Hong, SY Zhu, L Jiang, XQ Wang, NH Tang, FF She, YL Chen
    Onco Targets Ther, 2018;11(0):2875-2890.
    Species: Human
    Sample Types: Cell Culture Supernates
  7. Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
    Authors: AR Harris, MJ Perez, JM Munson
    BMC Cancer, 2018;18(1):718.
    Species: Mouse
    Sample Types: Tissue Homogenates
  8. cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF-?B pathway
    Authors: X Jiang, C Li, B Lin, H Hong, L Jiang, S Zhu, X Wang, N Tang, X Li, F She, Y Chen
    Cancer Sci., 2017;108(6):1144-1156.
    Species: Human
    Sample Types: Cell Culture Supernates
  9. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients
    Authors: David M Briscoe
    J. Heart Lung Transplant., 2016;0(0):.
    Species: Human
    Sample Types: Plasma
  10. Human neural stem cell-induced endothelial morphogenesis requires autocrine/paracrine and juxtacrine signaling
    Sci Rep, 2016;6(0):29029.
    Species: Human
    Sample Types: Cell Culture Supernates
  11. Effects of fatty acid synthase inhibitors on lymphatic vessels: an in vitro and in vivo study in a melanoma model
    Authors: Débora C Bastos
    Lab. Invest, 2016;0(0):.
    Species: Human
    Sample Types: Cell Culture Supernates
  12. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.
    Authors: Tutunea-Fatan, Elena, Majumder, Mousumi, Xin, Xiping, Lala, Peeyush
    Mol Cancer, 2015;14(1):35.
    Species: Human
    Sample Types: Cell Culture Supernates
  13. Identification of tumour-reactive lymphatic endothelial cells capable of inducing progression of gastric cancer.
    Authors: Tokumoto M, Tanaka H, Tauchi Y, Kasashima H, Kurata K, Yashiro M, Sakurai K, Toyokawa T, Kubo N, Amano R, Kimura K, Muguruma K, Maeda K, Ohira M, Hirakawa K
    Br J Cancer, 2015;113(7):1046-54.
    Species: Human
    Sample Types: Cell Culture Supernates
  14. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.
    Authors: Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, Jurgensmeier J, Giavazzi R, Belotti D
    Am J Pathol, 2014;184(4):1050-61.
    Species: Human
    Sample Types: Ascites Fluid
  15. KML001 inhibits cell proliferation and invasion in pancreatic cancer cells through suppression of NF-kappaB and VEGF-C.
    Authors: Yang M, Kim H, Lee K, Yang S, Lee J, Lee K, Rhee J
    Anticancer Res, 2014;34(7):3469-74.
    Species: Human
    Sample Types: Cell Culture Supernates
  16. Filarial excretory-secretory products induce human monocytes to produce lymphangiogenic mediators.
    Authors: Weinkopff T, Mackenzie C, Eversole R, Lammie P
    PLoS Negl Trop Dis, 2014;8(7):e2893.
    Species: Human
    Sample Types: Cell Culture Supernates
  17. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
    Authors: Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M
    BMC Cancer, 2014;14(0):696.
    Species: Human
    Sample Types: Serum
  18. Telmisartan, a possible PPAR-delta agonist, reduces TNF-alpha-stimulated VEGF-C production by inhibiting the p38MAPK/HSP27 pathway in human proximal renal tubular cells.
    Authors: Kimura H, Mikami D, Kamiyama K, Sugimoto H, Kasuno K, Takahashi N, Yoshida H, Iwano M
    Biochem Biophys Res Commun, 2014;454(2):320-7.
    Species: Human
    Sample Types: Cell Culture Supernates
  19. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
    Authors: Braicu E, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J
    Cytokine, 2013;61(3):755-8.
    Species: Human
    Sample Types: Serum
  20. Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
    Authors: Armstrong A, Haggman M, Stadler W, Gingrich J, Assikis V, Polikoff J, Damber J, Belkoff L, Nordle O, Forsberg G, Carducci M, Pili R
    Clin Cancer Res, 2013;19(24):6891-901.
    Species: Human
    Sample Types: Plasma
  21. Proteinuria triggers renal lymphangiogenesis prior to the development of interstitial fibrosis.
    Authors: Yazdani S, Poosti F, Kramer A, Mirkovic K, Kwakernaak A, Hovingh M, Slagman M, Sjollema K, de Borst M, Navis G, van Goor H, van den Born J
    PLoS ONE, 2012;7(11):e50209.
    Species: Human
    Sample Types: Cell Culture Supernates
  22. Lysophosphatidic Acid Enhances Vascular Endothelial Growth Factor-C Expression in Human Prostate Cancer PC-3 Cells.
    Authors: Lin CE, Chen SU, Lin CC
    PLoS ONE, 2012;7(7):e41096.
    Species: Human
    Sample Types: Cell Culture Supernates
  23. Co-expression of alpha9beta1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN.
    Authors: Majumder M, Tutunea-Fatan E, Xin X, Rodriguez-Torres M, Torres-Garcia J, Wiebe R, Timoshenko AV, Bhattacharjee RN, Chambers AF, Lala PK
    PLoS ONE, 2012;7(4):e35094.
    Species: Human
    Sample Types: Cell Culture Supernates
  24. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
    Authors: Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, Lim HY, Kim JS, Lechuga MJ, Lanzalone S, Lin X, Faivre S
    J Transl Med, 2011;9(0):120.
    Species: Human
    Sample Types: Plasma
  25. Prognostic significance of angiogenic factors in uterine cervical cancer.
    Authors: Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S
    Anticancer Res., 2011;31(8):2589-95.
    Species: Human
    Sample Types: Serum
  26. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast.
    Authors: Scheel C, Eaton E, Li S, Chaffer C, Reinhardt F, Kah K, Bell G, Guo W, Rubin J, Richardson A, Weinberg R
    Cell, 2011;145(6):926-40.
    Species: Human
    Sample Types: Cell Culture Supernates
  27. Human pregnancy specific beta-1-glycoprotein 1 (PSG1) has a potential role in placental vascular morphogenesis.
    Authors: Ha CT, Wu JA, Irmak S, Lisboa FA, Dizon AM, Warren JW, Ergun S, Dveksler GS
    Biol. Reprod., 2010;83(1):27-35.
    Species: Human
    Sample Types: Cell Culture Supernates
  28. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.
    Authors: Konings IR, de Jonge MJ, Burger H
    Br. J. Cancer, 2010;103(7):987-92.
    Species: Human
    Sample Types: Serum
  29. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism.
    Authors: Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Muller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, Van Rooijen N, Kurtz A, Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D, Titze J
    Nat. Med., 2009;15(5):545-52.
    Species: Human
    Sample Types: Serum
  30. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
    Authors: Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK
    J. Clin. Oncol., 2009;27(18):3027-35.
    Species: Human
    Sample Types: Plasma
  31. VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B.
    Authors: Onimaru M, Yonemitsu Y, Fujii T, Tanii M, Nakano T, Nakagawa K, Kohno R, Hasegawa M, Nishikawa S, Sueishi K
    Am. J. Physiol. Heart Circ. Physiol., 2009;297(5):H1685-96.
    Species: Human
    Sample Types: Serum
  32. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Authors: Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ
    J. Clin. Oncol., 2008;26(22):3743-8.
    Species: Human
    Sample Types: Plasma
  33. Isolation and characterization of CD146+ multipotent mesenchymal stromal cells.
    Authors: Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, Baiocchi M, Fatica A, Negrini M, Peschle C, Valtieri M
    Exp. Hematol., 2008;36(8):1035-46.
    Species: Human
    Sample Types: Cell Culture Supernates
  34. Cutting edge: rapid accumulation of epidermal CCL27 in skin-draining lymph nodes following topical application of a contact sensitizer recruits CCR10-expressing T cells.
    Authors: Huang V, Lonsdorf AS, Fang L, Kakinuma T, Lee VC, Cha E, Zhang H, Nagao K, Zaleska M, Olszewski WL, Hwang ST
    J. Immunol., 2008;180(10):6462-6.
    Species: Human
    Sample Types: Serum
  35. Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines.
    Authors: Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ
    Int. J. Oncol., 2008;32(3):585-92.
    Species: Human
    Sample Types: Cell Culture Supernates
  36. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.
    Authors: Lee CY, Tien HF, Hu CY, Chou WC, Lin LI
    Br. J. Cancer, 2007;97(7):877-82.
    Species: Human
    Sample Types: Plasma
  37. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
    Authors: Laakkonen P, Waltari M, Holopainen T, Takahashi T, Pytowski B, Steiner P, Hicklin D, Persaud K, Tonra JR, Witte L, Alitalo K
    Cancer Res., 2007;67(2):593-9.
    Species: Human
    Sample Types: Cell Culture Supernates
  38. Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts.
    Authors: Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E, Petrucci E, Cedrone M, Lo-Coco F, Foa R, Peschle C, Testa U
    Stem Cells, 2007;25(8):1862-71.
    Species: Human
    Sample Types: Cell Culture Supernates
  39. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
    Authors: Lin J, Lalani AS, Harding TC
    Cancer Res., 2005;65(15):6901-9.
    Species: Human
    Sample Types: Tissue Homogenates

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs

Reviews for Human VEGF-C Quantikine ELISA Kit

Average Rating: 4 (Based on 3 Reviews)

5 Star
33.33%
4 Star
33.33%
3 Star
33.33%
2 Star
0%
1 Star
0%

Have you used Human VEGF-C Quantikine ELISA Kit?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human VEGF-C Quantikine ELISA Kit
By Anonymous on 08/26/2020
Application: Sample Tested: HeLa cells

Human VEGF-C Quantikine ELISA Kit
By Anonymous on 12/12/2019
Application: Sample Tested: Human cell conditioned medium,Mouse cell conditioned medium

Works for mouse samples


Human VEGF-C Quantikine ELISA Kit
By Anonymous on 10/17/2019
Application: Sample Tested: 7TD1 mouse hybridoma cell line